TORONTO, ONTARIO, Sept. 16, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce, further to the press release dated September 10, 2026, the closing of the second tranche of a non-brokered private placement of the 15% unsecured convertible debentures (the “Offering”). In the second tranche of the Offering, the Company issued additional unsecured convertible debentures (the “Debentures”) in an aggregate principal amount of US$4,375,000 million, for an aggregate principal amount, together with the first closing, of US$10,706,250. The terms of the Offering contemplate the issuance of an aggregate principal amount of Debentures up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Completion of additional...

Gross Proceeds of $100,000,000 to Fund Exploration and Development of New Brunswick Properties Special Warrants Priced at $0.25 per Special Warrant Canaccord Genuity to Act as Lead Agent and Sole Bookrunner TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Osisko Critical Minerals Corporation (“OCMC” or the “Corporation“), a newly incorporated entity and a wholly-owned subsidiary of Osisko Metals Incorporated (“Osisko Metals“) (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51), is pleased to announce a best efforts private placement (the “Private Placement“) of special warrants of the Corporation (the “Special Warrants“) at a price of $0.25 per Special Warrant for gross proceeds of $100,000,000. The Private Placement will be led by Canaccord Genuity Corp. (“Canaccord Genuity“),...

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or “the Company”) today announced it will invest $6.2 million to expand production capacity at its Delta, BC facility. The investment will increase production volume by 15% from its current maximum capacity. Construction is expected to commence in Q1 2027 with no disruption to existing operations. The expansion is scheduled to be completed by June 2027 and operating commercially by July 2027. The Company anticipates internally financing the majority of the investment from operating cash flow, with the balance coming from existing credit lines. “Decaffeinated coffee drinkers are increasingly demanding that their coffee contain no residual chemical solvents. This continues to drive an industry-wide migration...

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats...

Stephen WillardStephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)Company Announces Exploration of All Options to Maximize Shareholder ValueThe top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron’s multiple clinical programs, and has shown potential efficacy in clinical studies across multiple indications and has received 5 designations from FDA Laromestrocel...

XTEND selected as a Gauntlet II leader in the Close Quarters Battle segment following successful delivery and demonstration of 120 STRIKER systems TAMPA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND) today announced that it was selected as a top performer in the close quarters battle segment of Gauntlet II of the U.S. Department of War’s iterative $1 billion Drone Dominance Program (DDP).The result follows XTEND’s successful delivery and demonstration of 120 STRIKER systems in operationally realistic scenarios evaluated by warfighters for Gauntlet II, and marks another significant milestone in the company’s growing role in U.S. defense programs. “This is a major win for XTEND,” said Aviv Shapira, Co-Founder and CEO of XTEND. “We delivered, we competed, and we proved what STRIKER is capable of in...

New York, NY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Churchill Capital Corp XIII (Nasdaq: XIIIU) (the “Company”) announced today that, commencing September 18, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “XIII” and “XIIIW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “XIIIU.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any...

Publicis Groupe successfully prices EUR 500 million of bond issue Paris – September 16, 2026 – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] announces that it has successfully priced its offering of EUR 500 million of notes due September 2030 (the “Notes”). The Notes are being issued under Publicis Groupe SA’s Euro Medium Term Note Program dated July 24, 2026. This bond will be issued by MMS USA Holdings Inc., a wholly-owned subsidiary of Publicis Groupe SA and unconditionnaly guaranteed by Publicis Groupe SA. The bonds carry a fixed annual coupon of 4.125%. The net proceeds of the bond issue will contribute to the financing of the acquisition of LiveRamp. As a reminder, the acquisition of LiveRamp remains subject to customary approvals and is expected to close before the end of 2026. The transaction has been led by Citi...